Latest Kaiser Health News Stories
Kaiser Health News reporter Sarah Jane Tribble sat down with Food and Drug Administration Commissioner Scott Gottlieb on C-SPAN’s “Newsmakers” program. The conversation ranged from how the nation should combat the opioid epidemic to reining in drug prices.
The Centers for Disease Control and Prevention found antibiotic-resistant bacteria whose spread has “outpaced” efforts to contain them.
Kaiser Health News gives readers a chance to comment on a recent batch of stories.
Almost three-quarters of Americans think the pharmaceutical industry has too much power in the nation’s capital, according to the Kaiser Family Foundation.
Though opioid prescriptions appear to be on the decline, Vicodin and Norco remain popular, especially in the South. In more than half of states, Synthroid — a drug to treat hypothyroidism — came in at No. 1.
How a prescription wiped out one woman’s health reimbursement account, raising questions about prescription drug price tags and about how health care professionals deal (or don’t) with medical costs.
Last month’s budget deal means Medicare beneficiaries are eligible for physical and occupational therapy indefinitely. Plus, prescription drug costs will fall for more seniors.
Researchers at the University of Southern California analyzed millions of prescriptions and concluded that close to a quarter paid copays that exceeded the cost of the drugs.
An addiction-treatment physician fatally shot a troubled ex-Marine after the man pummeled him inside his California office, police records show. The tragedy illustrates how the limited number of clinics available to prescribe buprenorphine, a drug that all but erases opioid withdrawal, can become crowded, chaotic and dangerous.
In this episode of KHN’s “What the Health?” Julie Rovner of Kaiser Health News, Margot Sanger-Katz of The New York Times, Joanne Kenen of Politico and new podcast panelist Anna Edney of Bloomberg News discuss this week’s spate of speeches by the leaders of the Department of Health and Human Services. They also discuss the slow progress on health legislation on Capitol Hill intended to fund the government and stabilize the individual insurance market. Plus, for extra credit, the panelists offer their favorite health policy stories of the week.
The market is flooded with 28 different medications for just 20,000 patients with the hereditary bleeding disorder. Yet intense competition hasn’t worked to bring costs down. Sales amount to $4.6 billion annually in the U.S.
A new study followed patients with severe chronic pain for a year and found that opioids relieved pain and increased function no better than common drugs like acetaminophen and lidocaine. But the opioids carry the risk of more serious side effects, including addiction and death.
Saving the lives of people with the bleeding disorder can require high doses of expensive blood-clotting factor. Taxpayers foot much of the bill as manufacturers profit enormously.
California’s health insurers trotted out a heart-healthy character with an ulterior motive — taking a dig at drugmakers.
Legislatures in blue and red states alike are considering proposals that would allow them to import prescription drugs from Canada.
In an exclusive interview, FDA Commissioner Scott Gottlieb describes what he’s doing to spur competition and bring down drug prices.
The Trump administration rolled out a list of actions to attack drug prices, but most dance around the edges.
Kaiser Health News Editor-in-Chief Elisabeth Rosenthal discusses drug costs with Scott Simon, the host of NPR’s Weekend Edition. Listen to the broadcast and read a transcript of that conversation.
In Louisiana, the wining and dining of lawmakers by scores of pharma lobbyists proves a valuable lesson on how to win statehouse votes and influence profits.
Amazon, Berkshire Hathaway and JPMorgan Chase & Co. are partnering up to address employee health care costs and improve satisfaction. Can they deliver? And would repackaging health insurance involve drones?